Drug Detail:Zanamivir (Zanamivir [ zan-am-i-vir ])
Drug Class: Inhaled anti-infectives Neuraminidase inhibitors
Zanamivir Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the use of zanamivir during breastfeeding. One group of authors estimated that an exclusively breastfed 5 kg infant would receive about 0.075 mg daily in breastmilk after an inhaled maternal dose of 10 mg, which is less than 1% of the dose in older children. In addition, because zanamivir is poorly absorbed orally, it is not likely to reach the bloodstream of the infant in clinically important amounts.[1]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Oseltamivir
References
- 1.
-
Tanaka T, Nakajima K, Murashima A, et al. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ. 2009;181:55–8. [PMC free article: PMC2704420] [PubMed: 19528139]
Substance Identification
Substance Name
Zanamivir
CAS Registry Number
139110-80-8
Drug Class
Breast Feeding
Lactation
Antiviral Agents
Neuraminidase Inhibitors
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification